Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Johnson & Johnson's COVID shot could return by late this week with some extra safety warnings: Fauci
CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more
White House to give CDC $1.7B to help find and track COVID-19 variants
With the competition struggling, Pfizer's COVID vaccine sales could hit $24B this year: analyst
FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys
Adagio raises a monster $336M round for bespoke COVID-19 drug battle
A look at how Blues plans are aiming to get their members vaccinated
Serum Institute nears $400M grant to boost AstraZeneca COVID shot production—just as material shortages mount
As variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibody
Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact
COVID-19 tracker: CVS, Walgreens offer at-home tests; Sputnik V highly effective in new study, developers say

Featured Story

Johnson & Johnson's COVID shot could return by late this week with some extra safety warnings: Fauci

By Fraiser Kansteiner

The U.S. will likely bring Johnson & Johnson's COVID-19 vaccine back into its immunization scheme, alongside some new restrictions or safety warnings, NIAID director Anthony Fauci said. The country should know by Friday when it can expect to see the single-dose vaccine back on the menu.

CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more

By Conor Hale

After spending months churning out tens of millions of its card-sized coronavirus antigen tests, Abbott has begun shipping the BinaxNOW tests nationwide to CVS, Walgreens and Walmart stores.

White House to give CDC $1.7B to help find and track COVID-19 variants

By Robert King

The White House announced a new investment of $1.7 billion to help the CDC track down the spread of more transmissible variants of COVID-19.

With the competition struggling, Pfizer's COVID vaccine sales could hit $24B this year: analyst

By Kevin Dunleavy

With the COVID-19 vaccine landscape shifting in favor of mRNA shots, Bernstein analyst Ronny Gal predicts $24 billion in sales for Pfizer and $14 billion for Moderna this year. The prediction comes amid setbacks for the Johnson & Johnson and AstraZeneca vaccines on both sides of the Atlantic.

FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys

By Kevin Dunleavy

Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant didn’t last long. At the FDA's request, Emergent stopped production just two weeks after J&J took over manufacturing its shot there.

Adagio raises a monster $336M round for bespoke COVID-19 drug battle

By Ben Adams

Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year.

A look at how Blues plans are aiming to get their members vaccinated

By Paige Minemyer

As a number of states open vaccine eligibility to more adults, Blues insurers across the country are aiming to be a community resource to ensure shots are administered.

Serum Institute nears $400M grant to boost AstraZeneca COVID shot production—just as material shortages mount

By Fraiser Kansteiner

Serum Institute of India is close to winning a $400 million grant from the government to boost production of AstraZeneca's COVID-19 vaccine, The Economic Times reports. The news comes as the company continues to face supply shortfalls, thanks to export controls imposed in the U.S.

As variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibody

By Noah Higgins-Dunn

The FDA has revoked its emergency authorization for Eli Lilly's solo COVID-19 antibody treatment, bamlanivimab, because the drug's benefits no longer outweigh its risks against emerging coronavirus variants. Lilly had called for the med's authorization to be pulled.

Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact

By Ben Adams

Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19.

COVID-19 tracker: CVS, Walgreens offer at-home tests; Sputnik V highly effective in new study, developers say

By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky

CVS and Walgreens are rolling out at-home rapid tests that can be purchased without a prescription. Israel said it inked a new vaccine supply deal with Pfizer and BioNTech. The vaccine developers behind Russia's Sputnik V said a new study found the shot to be 97.6% effective against COVID-19. And more headlines.

COVID-19 Tracker